文献速递主动脉疾病

有无既往腹部血管腔内或开放手术修复史患者行开窗分支血管腔内主动脉修复术的结局

Outcomes of fenestrated-branched endovascular aortic repair in patients with or without prior history of abdominal endovascular or open surgical repair.
PubMed 文献 · J Vasc Surg · 2023-04-19

本研究为前瞻性非随机研究,纳入506例复杂腹主动脉瘤或胸腹主动脉瘤患者行开窗分支血管腔内主动脉修复术(FB-EVAR),比较无既往修复史(对照组380例)、既往EVAR(1组54例)和既往腹部开放手术(2组72例)的结局。三组技术成功率96%、死亡率1%、主要不良事件率14%无差异;2组患者生存率显著较低,1组II型内漏和瘤囊增大无事件率较低,2组新发永久透析无事件率较低。

要点

  • FB-EVAR在有无既往腹部主动脉修复史患者中技术成功率高、死亡率低、主要不良事件风险相似。
  • 既往腹部开放手术患者生存率显著较低,但主动脉相关死亡和二次干预无事件率相似。
  • 既往EVAR患者II型内漏和瘤囊增大无事件率较低;既往开放手术患者新发永久透析无事件率较低。

核心结论

  • FB-EVAR无论有无既往腹部主动脉修复史,均具有高技术成功率、低死亡率和相似的主要不良事件风险。
  • 既往腹部开放手术患者生存率显著较低,但主动脉相关死亡和二次干预无事件率组间相似。
  • 既往EVAR患者II型内漏和瘤囊增大无事件率较低;既往开放手术患者新发永久透析无事件率较低。

研究设计与样本

  • 前瞻性非随机研究,评估FB-EVAR治疗复杂腹主动脉瘤和胸腹主动脉瘤的连续患者临床数据。
  • 共506例患者(男性69%;平均年龄72±9岁),包括对照组380例、1组(既往EVAR)54例、2组(既往腹部开放手术)72例。
  • 动脉瘤范围为复杂腹主动脉瘤144例(28%)和胸腹主动脉瘤362例(72%)。

主要发现

  • FB-EVAR分别在索引EVAR后平均7±4年和腹部开放手术后平均12±6年进行(P < .001)。
  • 三组临床特征相似,但对照组冠状动脉疾病较少,2组胸腹主动脉瘤和分支支架设计较多(P < .05)。
  • 总体技术成功率96%、死亡率1%、主要不良事件率14%,组间无差异。
  • 平均随访30±21个月,2组患者生存率显著较低(P = .03),但5年主动脉相关死亡和二次干预无事件率组间无差异。
  • 1组任何II型内漏无事件率较低(P = .02)和瘤囊增大(≥5 mm)无事件率较低(P < .001),2组新发永久透析无事件率较低(P = .03)。

关键数值与推荐

  • 技术成功定义为总体技术成功率96%,死亡率1%,主要不良事件率14%。
  • 瘤囊增大定义为≥5 mm。
  • 随访时间平均30±21个月。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to compare outcomes of fenestrated-branched endovascular aortic repair (FB-EVAR) of complex abdominal (CAAAs) and thoracoabdominal aortic aneurysms (TAAAs) in patients with or without prior history of abdominal open surgical (OSR) or endovascular aortic repair (EVAR). METHODS: The clinical data of consecutive patients enrolled in a prospective, non-randomized study to evaluate FB-EVAR for treatment of CAAAs and TAAAs was reviewed. Clinical outcomes were analyzed in patients with no previous aortic repair (Controls), prior EVAR (Group 1), and prior abdominal OSR (Group 2), including 30-day mortality and major adverse events (MAEs), patient survival and freedom from aortic-related mortality (ARM), secondary interventions, any type II endoleak, sac enlargement (≥5 mm), and new-onset permanent dialysis. RESULTS: There were 506 patients (69% male; mean age, 72 ± 9 years) treated by FB-EVAR, including 380 controls, 54 patients in Group 1 (EVAR), and 72 patients in Group 2 (abdominal OSR). FB-EVAR was performed on average 7 ± 4 and 12 ± 6 years after the index EVAR and abdominal OSR, respectively (P < .001). All three groups had similar clinical characteristics, except for less coronary artery disease in controls and more TAAAs and branch stent graft designs in Group 2 (P < .05). Aneurysm extent was CAAA in 144 patients (28%) and TAAA in 362 patients (72%). Overall technical success, mortality, and MAE rate were 96%, 1%, and 14%, respectively, with no difference between groups. Mean follow up was 30 ± 21 months. Patient survival was significantly lower in Group 2 (P = .03), but there was no difference in freedom from ARM and secondary interventions at 5 years between groups. Group 1 patients had lower freedom from any type II endoleak (P = .02) and sac enlargement (P < .001), whereas Group 2 patients had lower freedom from new-onset permanent dialysis (P = .03). CONCLUSIONS: FB-EVAR was performed with high technical success, low mortality, and similar risk of MAEs, regardless of prior history of abdominal aortic repair. Patient survival was significantly lower in patients who had previous abdominal OSR, but freedom from ARM and secondary interventions were similar among groups. Patients with prior EVAR had lower freedom from type II endoleak and sac enlargement. Patients with prior OSR had lower freedom from new-onset dialysis.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Vacirca A, Wong J, Baghbani A, et al. Outcomes of fenestrated-branched endovascular aortic repair in patients with or without prior history of abdominal endovascular or open surgical repair. J Vasc Surg. 2023. PMID: 37080442. doi:10.1016/j.jvs.2023.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。